A Double-Blind, Randomized, Placebo-Controlled, Parallel-Group, Multicenter Study of MK0928 in Healthy Adult Volunteers Participating in a 4-Hour Phase Advance Model of Transient Insomnia

NCT00102154 Phase 3 WITHDRAWN

A study to evaluate the safety and effectiveness of an investigational drug for insomnia (a sleep disorder).

Details

Lead sponsor	H. Lundbeck A/S
Phase	Phase 3
Status	WITHDRAWN
Start date	2005-01

Conditions

• Insomnia

Interventions

• MK0928, gaboxadol / Duration of Treatment: 10 months

Primary outcomes

• 4-hour advanced polysomnographic (PSG) recording session measuring wake time after sleep onset (WASO) and latency to persistent sleep (LPS); Safety and tolerability